查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012893

出血性疾病治疗市场：2026-2032年全球市场预测（按产品类型、治疗方法、给药途径、适应症、分销管道和最终用户划分）

Bleeding Disorders Treatment Market by Product Type, Treatment Type, Route Of Administration, Disease Indication, Distribution Channel, End Users - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，出血性疾病治疗市场价值将达到 160.4 亿美元，到 2026 年将成长至 173.8 亿美元，到 2032 年将达到 307.4 亿美元，复合年增长率为 9.73%。

主要市场统计数据
基准年 2025 160.4亿美元
预计年份：2026年 173.8亿美元
预测年份 2032 307.4亿美元
复合年增长率 (%) 9.73%

对目前正在重塑出血性疾病治疗路径和护理模式的临床、交付和相关人员趋势进行权威概述。

出血性疾病的治疗正处于临床创新和医疗服务体系快速发展的时期，治疗方法的进步和以患者为中心的护理模式正在重塑临床实践。这包括新的生物製药，它们正在重新定义医疗服务的提供方式，以及长期以来对治疗药物的分类。同时，生物製药的监管也在不断完善，并且越来越重视基于价值的医疗服务获取，这使得製药公司、临床医生和支付方面临着更为复杂的环境。

分子层面的创新、管理方法的进步以及不断发展的支付方和护理模式如何为出血性疾病的整体治疗带来系统性的变革？

在出血性疾病领域，分子疗法的进步、给药技术的改进以及以患者自主性为核心的护理模式的演变，正在推动变革性的变化。基因疗法和基因修饰凝血因子的发展促使人们重新评估长期疾病管理策略，而製剂和给药方法的创新则将预防性护理的选择范围扩展到了传统医院环境之外。这些变化正在改变临床医生开立处方的方式以及患者参与自身护理计划的方式。

本研究评估了 2025 年美国关税调整将如何影响出血性疾病治疗供应链的韧性、筹资策略和商业规划。

到2025年，美国关税政策变化的累积影响将成为影响出血性疾病治疗供应链策略和商业计画的关键因素。关税调整正在影响原料和零件的采购决策，促使製造商重新考虑供应商多元化和近岸外包方案，以降低跨境成本波动带来的风险。这些变化正在加速供应商合约的重新谈判，各组织要求提高价格透明度并加强风险分担机制。

综合细分洞察揭示了产品分类、治疗方法、给药途径、最终用户、分销管道和适应症如何驱动差异化策略。

基于细分市场的洞察揭示了产品类型、治疗方法、给药途径、终端用户环境、分销管道和适应症等方面的显着差异，这些差异均有助于制定个人化的商业策略。依产品类型划分，市场涵盖抗纤溶药物、凝血因子和去氨加压素，其中凝血因子可进一步细分为血浆来源製剂和重组製剂。了解血浆来源製剂和重组製剂在临床特征和生产结构上的差异对于市场定位和供应计划至关重要。按治疗类型划分，按需治疗和预防性治疗之间有明显的差异。预防性治疗强调支持长期用药依从性和病患教育，而按需治疗则着重于急性期用药和快速反应途径。

区域趋势和差异化的市场进入方式对于优化全球商业化、供应链和市场准入策略至关重要。

区域趋势对于解读全球市场的采纳模式、报销环境和供应链设计仍然至关重要。美洲地区拥有丰富的临床专业知识、成熟的治疗中心以及不断发展的支付模式，这些模式强调实证医学的进入途径。这些因素塑造了以可靠的真实世界数据和与支付方的合作为优先的商业化策略。欧洲、中东和非洲地区由于法规结构和报销体系的差异，需要根据具体情况调整上市顺序和区域价值提案。同时，一些国家拥有成熟的高品质医疗中心，能够支持先进治疗方法的早期应用。

业内公司如何协调临床创新、伙伴关係和生命週期管理，以实现商业性差异化并确保患者获得治疗？

竞争格局呈现出由成熟的生物製药企业、专业生物技术公司以及专注于分销、患者支持和诊断的服务供应商组成的多元化格局。主要企业正加大对实证医学计画、製剂改进和新型给药系统的投入，以实现持续的临床差异化。随着各机构寻求确保供应连续性并扩大居家照护服务能力，研发企业与专业药局和物流供应商之间的策略合作日益普遍。

为行业领导者提供切实可行的建议，以协调证据产生、供应链韧性和相关人员合作，从而确保患者能够可靠地获得治疗。

为了将科学进步转化为可及的治疗方法，产业领导者应优先考虑跨部门合作，将临床开发、供应链运作和市场进入连接起来。早期投资于产生真实世界数据（REWID）可以降低与保险公司谈判的风险，并支持差异化的价值提案。同时，并行规划低温运输物流和替代采购路线可以降低关税波动和地缘政治风险的影响。这些相辅相成的努力确保了临床疗效得到营运可靠性的支持。

采用透明的混合方法研究途径，结合临床医师访谈、政策检讨和比较細項分析，为策略决策提供支援。

本调查方法结合了多种一手和二手研究途径，旨在建立稳健的证据基础，并维持严格的品管。一手研究包括对临床医生、供应链专家、支付方和患者权益倡导团体代表进行结构化访谈，以收集关于治疗方法采纳、诊疗路径和就医障碍的第一手资料。这些定性资讯与监管文件、已发表的临床数据和公共文件进行交叉核对，以确保其与当前的临床和法律规范保持一致。

透过整合治疗创新、营运韧性和支付方合作，改善病患就医途径和治疗效果，从而概述策略挑战。

总而言之，出血性疾病的治疗格局呈现出快速的临床创新、不断演变的医疗服务模式以及对营运韧性和支付方参与度日益增长的关注等特点。治疗方法和给药途径的进步为改善患者体验和治疗效果创造了重要机会，但成功实施需要跨地区和跨医疗机构的协作策略，以协调临床证据、供应链能力和利益相关人员的参与。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 出血性疾病治疗市场：依产品类型划分

  • 抗纤溶药物
  • 凝血因子
    • 血浆衍生的
    • 重组
  • 去氨加压素

第九章：出血性疾病治疗市场（依治疗类型划分）

  • 必要时
  • 预防

第十章 出血性疾病治疗市场：依给药途径划分

  • 静脉
  • 口服
  • 皮下

第十一章 出血性疾病治疗市场：依疾病适应症划分

  • A型血友病
  • B型血友病
  • 血管性血友病

第十二章 出血性疾病治疗市场：依分销管道划分

  • 电子商务
  • 医院药房
  • 零售药房

第十三章 出血性疾病治疗市场：依最终用户划分

  • 居家医疗
  • 医院
  • 专科诊所

第十四章 出血性疾病治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 出血性疾病治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 出血性疾病治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国出血性疾病治疗市场

第十八章 中国出血性疾病治疗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Alnylam Pharmaceuticals
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Bristol-Myers Squibb
  • CSL Limited
  • F. Hoffmann-La Roche Ltd
  • Ferring Pharmaceuticals
  • Grifols, SA
  • Janssen Pharmaceuticals
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceuticals Pvt. Ltd.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Zydus Lifesciences
Product Code: MRR-437D45957F02

The Bleeding Disorders Treatment Market was valued at USD 16.04 billion in 2025 and is projected to grow to USD 17.38 billion in 2026, with a CAGR of 9.73%, reaching USD 30.74 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.04 billion
Estimated Year [2026] USD 17.38 billion
Forecast Year [2032] USD 30.74 billion
CAGR (%) 9.73%

An authoritative introduction to current clinical, delivery, and stakeholder dynamics reshaping bleeding disorders treatment pathways and care models

Bleeding disorders treatment is undergoing a phase of intense clinical innovation and delivery evolution, where therapeutic advances and patient-centric care models are reshaping clinical practice. The landscape includes long-standing therapeutic classes alongside newer biologics and patient-administered formulations that have redefined how care is delivered across settings. These changes are occurring concurrently with regulatory refinement around biologics and greater emphasis on value-based access, creating a more complex environment for manufacturers, clinicians, and payers.

Clinicians are balancing efficacy and safety considerations with practical concerns such as ease of administration and the ability to support home-based care. Patients and caregivers are demanding treatments that minimize disruption to daily life while offering predictable bleeding control. Payers are increasingly attentive to long-term outcomes and total cost of care, which is influencing coverage decisions and prior authorization protocols. As a result, stakeholders must navigate an interconnected system of clinical evidence generation, real-world data collection, and stakeholder engagement to achieve broad adoption.

This report synthesizes clinical, operational, and commercial dimensions to support informed decisions. It emphasizes actionable insights into treatment modalities, care settings, and stakeholder priorities. The goal is to equip executives and clinical leaders with a clear view of the forces shaping the therapeutic environment and the pragmatic considerations required to translate advances into sustainable patient access.

How molecular innovations, delivery advances, and evolving payer and care models are driving systemic transformation across bleeding disorders treatment

The bleeding disorders field is experiencing transformative shifts driven by advances in molecular therapies, improvements in delivery technologies, and evolving care models that prioritize patient autonomy. Gene therapy developments and engineered clotting factors are prompting reevaluation of long-term disease management strategies, while innovations in formulation and administration are expanding options for prophylactic care outside traditional hospital environments. These shifts are changing how clinicians prescribe treatments and how patients engage with their care plans.

Concurrently, digital health solutions and remote monitoring are facilitating greater adherence oversight and earlier intervention, which in turn supports the expansion of home care settings. Payer frameworks are adapting to incorporate outcomes-based contracting and to appraise novel therapies on longer-term clinical and economic metrics. Supply chain optimization and cold-chain logistics improvements are enabling broader distribution of biologics, yet they require new operational competencies among manufacturers and distributors.

Taken together, these transformations are creating opportunities for differentiated clinical profiles and delivery models to gain traction. Organizations that align clinical development with real-world evidence collection, optimized distribution, and payer engagement will be better positioned to convert therapeutic innovation into meaningful improvements in patient outcomes and health system efficiency.

Assessing how 2025 United States tariff adjustments are reshaping supply chain resilience, procurement strategies, and commercial planning for bleeding disorders therapies

In 2025 the cumulative impact of tariff policy changes in the United States is an important factor shaping supply chain strategies and commercial planning for therapies used in bleeding disorders. Tariff adjustments have influenced sourcing decisions for raw materials and components, prompting manufacturers to reassess supplier diversification and nearshoring options to reduce exposure to cross-border cost volatility. These shifts have catalyzed renegotiation of supplier contracts, with organizations seeking greater price transparency and risk-sharing mechanisms.

At the operational level, distributors and manufacturers have prioritized resilience by increasing inventory buffers for critical biologic inputs and by investing in alternative logistics routes. These measures come with higher holding costs and more complex inventory management, but they mitigate the risk of interruptions that could affect product availability and patient continuity of care. In parallel, procurement teams are intensifying supplier qualification processes and expanding audits to ensure compliance with evolving tariff-related documentation and classification requirements.

Strategically, market access teams are engaging earlier with payers and health systems to communicate the clinical and operational rationale for pricing and to demonstrate steps taken to sustain supply reliability. The net effect is a greater emphasis on integrated commercial and supply chain planning that aligns regulatory compliance, cost management, and patient access objectives under conditions of tariff-driven uncertainty.

Integrated segmentation insights revealing how product class, treatment approach, administration route, end users, distribution channels, and indications drive differentiated strategies

Segmentation-driven insights reveal meaningful differentiation across product types, treatment approaches, administration routes, end-user settings, distribution channels, and disease indications, each of which informs tailored commercial strategies. Based on Product Type the market encompasses Anti Fibrinolytics, Clotting Factors, and Desmopressin, with Clotting Factors further delineated into Plasma Derived and Recombinant options; recognizing the distinct clinical profiles and manufacturing footprints of plasma-derived versus recombinant agents is essential for positioning and supply planning. Based on Treatment Type there are clear contrasts between On Demand and Prophylactic approaches, where prophylactic regimens emphasize long-term adherence support and patient education while on-demand therapies focus on acute access and rapid response pathways.

Based on Route Of Administration therapies distributed intravenously, administered orally, or delivered subcutaneously each carry unique implications for clinical workflow, training requirements, and patient preference; subcutaneous and oral formulations generally lower the barrier to home administration and can improve treatment adherence. Based on End Users the care continuum spans Home Care Settings, Hospitals, and Specialty Clinics, and each setting demands distinct support models, from remote monitoring capabilities for home care to structured infusion infrastructure in hospital environments. Based on Distribution Channel there are differences in channel economics and patient touchpoints across E Commerce, Hospital Pharmacy, and Retail Pharmacy, which affect fulfillment models and opportunities for patient support services. Finally, based on Disease Indication the clinical focus varies by Hemophilia A, Hemophilia B, and Von Willebrand Disease, each requiring differentiated clinical data, patient education, and long-term management strategies. Understanding how these segmentation dimensions intersect enables more precise targeting of clinical evidence generation, commercial deployment, and stakeholder engagement.

Regional dynamics and differentiated market entry approaches essential for tailoring commercialization, supply chain, and access strategies across global territories

Regional dynamics remain a critical axis for interpreting adoption patterns, reimbursement environments, and supply chain design across global markets. In the Americas there is concentrated clinical expertise, established treatment centers, and evolving payer models that favor evidence-based access pathways; these factors shape commercialization tactics that emphasize robust real-world evidence and payer engagement. In Europe, Middle East & Africa diverse regulatory frameworks and heterogeneous reimbursement systems necessitate adaptive launch sequencing and localized value dossiers, while established centers of excellence in some countries support early adoption of advanced therapies.

In Asia-Pacific the market is characterized by rapid growth in clinical capacity, variable payer penetration, and an increasing emphasis on localized manufacturing and distribution partnerships to meet demand and cost expectations. Across regions, logistics and cold-chain considerations differ significantly and require region-specific approaches to inventory management, cold storage infrastructure, and distribution partnerships. Moreover, patient advocacy and specialist networks vary in maturity, influencing awareness campaigns and the structure of patient support programs.

Taken together, regional insights highlight the need for nuanced market entry plans that incorporate local regulatory pathways, distributor capabilities, and stakeholder engagement strategies. Companies that tailor clinical evidence packages, pricing approaches, and support models to regional realities will be better positioned to accelerate appropriate patient access and maintain sustainable supply operations.

How industry players are aligning clinical innovation, partnerships, and lifecycle management to secure commercial differentiation and ensure patient access

Competitor and collaborator landscapes reflect a mix of established biologics manufacturers, specialty biotech firms, and service providers focused on distribution, patient support, and diagnostics. Key companies are investing in extended evidence generation programs, formulation improvements, and novel delivery systems to create durable clinical differentiation. Strategic partnerships between developers and specialty pharmacies or logistics providers are becoming more common as organizations seek to ensure continuity of supply and to expand capabilities for home-based care delivery.

Companies are also focusing on lifecycle management strategies for legacy products, including reformulations and digital adherence solutions, to sustain clinical relevance while new entrants introduce differentiated mechanisms of action. Across the sector, there is a convergence of clinical, regulatory, and commercial activities: regulatory submissions increasingly incorporate patient-reported outcomes and health economics data, while commercial teams build value stories that connect clinical benefit to system-level cost outcomes. Collaboration between clinical affairs, market access, and supply chain functions is critical to operationalize pipeline innovations and to translate them into real-world patient benefit.

As competition intensifies, organizations that integrate R&D planning with pragmatic commercialization playbooks, invest in robust pharmacovigilance and real-world evidence collection, and develop strong partnerships across the care continuum will create the most defensible positions in the evolving treatment landscape.

Actionable recommendations for industry leaders to align evidence generation, supply chain resilience, and stakeholder engagement for reliable patient access

To translate scientific advances into accessible therapies, industry leaders should prioritize cross-functional alignment that bridges clinical development, supply chain operations, and market access. Investing early in real-world evidence generation can de-risk payer conversations and support differentiated value propositions, while parallel planning for cold-chain logistics and alternate sourcing reduces vulnerability to tariff-induced and geopolitical disruptions. These complementary actions ensure that clinical benefits are supported by operational reliability.

In addition, companies should adopt targeted patient engagement and education programs that reflect the nuances of administration routes and care settings; enabling patients and caregivers to manage prophylactic or home-administered regimens effectively will improve adherence and outcomes. Strategic distribution partnerships and selective use of e-commerce and specialty pharmacy channels can enhance convenience and continuity of supply. Carefully designed pricing and contracting strategies that incorporate outcome-based elements where feasible will facilitate constructive payer dialogue.

Finally, leadership should foster adaptable commercialization playbooks that incorporate modular data packages and region-specific launch sequences. Such flexibility enables rapid response to regional regulatory requirements and local payer expectations, while preserving the ability to scale successful approaches across geographies. By aligning evidence generation, operational resilience, and stakeholder engagement, organizations can more reliably convert therapeutic innovation into patient-centered outcomes.

A transparent mixed-methods research approach integrating clinician interviews, policy review, and comparative segmentation analysis to support strategic decision-making

The research methodology combines multi-source primary and secondary approaches to create a robust evidence base for analysis while maintaining rigorous quality controls. Primary research included structured interviews with clinicians, supply chain specialists, payers, and patient advocacy representatives to capture experiential insights on treatment adoption, care pathways, and access barriers. These qualitative inputs were triangulated with regulatory filings, published clinical data, and public policy documents to ensure alignment with current clinical and regulatory frameworks.

Analytical methods emphasized comparative assessment across segmentation dimensions and regional contexts, evaluating differences in clinical practice, delivery infrastructure, and distribution channels. Data validation steps included cross-referencing interview insights with operational indicators reported in public health and regulatory documentation, and subject-matter expert review to ensure clinical accuracy. Where appropriate, scenario analyses were used to surface strategic implications of supply chain and policy changes without projecting market sizes or forecasts.

The methodology was designed to facilitate actionable conclusions by focusing on decision-relevant metrics, stakeholder priorities, and operational imperatives. Transparency in interview protocols and validation steps ensures reproducibility of key interpretive outcomes and allows stakeholders to trace how evidence informed strategic recommendations.

Concluding synthesis of strategic imperatives that link therapeutic innovation, operational resilience, and payer engagement to improve patient access and outcomes

In summary, the bleeding disorders treatment landscape is characterized by rapid clinical innovation, evolving delivery models, and heightened attention to operational resilience and payer engagement. Advances in therapeutic modalities and administration routes are creating meaningful opportunities to improve patient experience and outcomes, but successful adoption depends on coordinated strategies that align clinical evidence, supply chain capabilities, and stakeholder engagement across regions and care settings.

Organizations that proactively address regional regulatory differences, invest in real-world evidence, and strengthen distribution and home-care capabilities will be better positioned to navigate access pathways and sustain product availability. The cumulative effect of tariff and policy changes further reinforces the need for diversified sourcing, adaptive procurement practices, and strong partnerships across logistics and specialty pharmacy networks. Ultimately, converting scientific progress into reliable patient access requires integrated planning across R&D, operations, and commercial functions.

This executive synthesis highlights the core strategic levers that leaders should prioritize to balance innovation with practical access considerations. Stakeholders that align evidence generation with pragmatic deployment models and payer-focused value narratives will most effectively translate therapeutic advances into measurable patient benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bleeding Disorders Treatment Market, by Product Type

  • 8.1. Anti Fibrinolytics
  • 8.2. Clotting Factors
    • 8.2.1. Plasma Derived
    • 8.2.2. Recombinant
  • 8.3. Desmopressin

9. Bleeding Disorders Treatment Market, by Treatment Type

  • 9.1. On Demand
  • 9.2. Prophylactic

10. Bleeding Disorders Treatment Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Bleeding Disorders Treatment Market, by Disease Indication

  • 11.1. Hemophilia A
  • 11.2. Hemophilia B
  • 11.3. Von Willebrand Disease

12. Bleeding Disorders Treatment Market, by Distribution Channel

  • 12.1. E Commerce
  • 12.2. Hospital Pharmacy
  • 12.3. Retail Pharmacy

13. Bleeding Disorders Treatment Market, by End Users

  • 13.1. Home Care Settings
  • 13.2. Hospitals
  • 13.3. Specialty Clinics

14. Bleeding Disorders Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Bleeding Disorders Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Bleeding Disorders Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Bleeding Disorders Treatment Market

18. China Bleeding Disorders Treatment Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Alnylam Pharmaceuticals
  • 19.7. Bayer AG
  • 19.8. Biogen Inc.
  • 19.9. BioMarin Pharmaceutical Inc.
  • 19.10. Bristol-Myers Squibb
  • 19.11. CSL Limited
  • 19.12. F. Hoffmann-La Roche Ltd
  • 19.13. Ferring Pharmaceuticals
  • 19.14. Grifols, S.A.
  • 19.15. Janssen Pharmaceuticals
  • 19.16. Novo Nordisk A/S
  • 19.17. Octapharma AG
  • 19.18. Pfizer Inc.
  • 19.19. Sanofi S.A.
  • 19.20. Sun Pharmaceuticals Pvt. Ltd.
  • 19.21. Swedish Orphan Biovitrum AB
  • 19.22. Takeda Pharmaceutical Company Limited
  • 19.23. Zydus Lifesciences

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLEEDING DISORDERS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ANTI FIBRINOLYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ANTI FIBRINOLYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ANTI FIBRINOLYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PLASMA DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PLASMA DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON DEMAND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON DEMAND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON DEMAND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HEMOPHILIA A, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HEMOPHILIA A, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HEMOPHILIA B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HEMOPHILIA B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY VON WILLEBRAND DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY VON WILLEBRAND DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY E COMMERCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY E COMMERCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY E COMMERCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 140. GCC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2032 (USD MILLION)
  • TABLE 143. GCC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. GCC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. GCC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. GCC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. GCC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 164. G7 BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2032 (USD MILLION)
  • TABLE 167. G7 BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. G7 BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. G7 BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. G7 BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. G7 BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 172. NATO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2032 (USD MILLION)
  • TABLE 175. NATO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. NATO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. NATO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. NATO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CLOTTING FACTORS, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)